Dragonfly Therapeutics, Inc.
35 Gatehouse Drive
8 articles with Dragonfly Therapeutics, Inc.
Dragonfly Therapeutics Announces Merck Opt-In of TriNKET™ Immunotherapy Candidate for Patients with Solid Tumors
Dragonfly Therapeutics, Inc. ("Dragonfly"), today announced that Merck, known as MSD outside the United States and Canada , has licensed its first TriNKET™ immunotherapy candidate from Dragonf
Bristol Myers Squibb plunked down $475 million for the exclusive license to Dragonfly Therapeutics’ interleukin-12 (IL-12) investigational immunotherapy program.
Dragonfly Therapeutics, Inc. ("Dragonfly" or the "Company"), today announced that Bristol Myers Squibb ("BMS") has licensed its fourth TriNKET™ immunotherapy drug candidate from Dr
Dragonfly Therapeutics Initiates Phase 1/2 Study of its IL12 Immunotherapy in Patients with Advanced Solid Tumors
The company announces its first patient enrolled and dosed in a Phase 1/2 clinical trial evaluating its novel IL12 cytokine, DF6002.
Dragonfly Therapeutics Announces New Research Collaboration with Bristol Myers Squibb to Develop Novel Therapeutic Candidates for Multiple Sclerosis and Neuro-inflammation Target
Dragonfly expands beyond existing collaboration with Bristol Myers Squibb in oncology and autoimmune disease to develop drug candidates against multiple targets using its proprietary platform in new therapeutic areas WALTHAM, Mass., July 6, 202
Dragonfly Therapeutics, Inc. ("Dragonfly"), today announced that Dr. Tapan Maniar has been appointed SVP and Head of Clinical Development and will join the senior team
Dragonfly Therapeutics, Inc. ("Dragonfly" or the "Company") today announced that Fidelity Management & Research Company ("Fidelity") has led a new round of investment in Dragonfly, along with other major investors.
Dragonfly Therapeutics Announces Multi-Target Expansion of its Collaboration with Merck to Use Dragonfly's Proprietary TriNKET™ Platform to Develop Novel Therapeutic Candidates in the fields of Oncology, Infectious Disease, and Immune Disorders
Dragonfly Therapeutics, Inc. ("Dragonfly"), today announced an expansion of its strategic collaboration with Merck, known as MSD outside the United States and Canada to discover, develop and commercialize a number of Dragonfly's candidate natural killer ("NK") cell engager immunotherapies for oncology, infectious disease, and immune disorders.